In HCC, the clinical benefit of DNA-PKcs inhibition has been actively exploited because increased expression and activity of DNA-PKcs is an independent biomarker for poor survival in HCC [21–23]. This evidence concerns the gene PRKDC and hepatocellular carcinoma.